Proteogenomic analysis of 5,411 plasma proteins in sickle cell disease patients
PLOS Genetics · 16.11.2026 · 22 (11) · e1012377
DOI: 10.1371/journal.pgen.1012377 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, online erschienen am 16.11.2026. Verfasst von Cristian Groza und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université de Montréal, Montréal, Québec, Canada. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute of Genetics, Canada Research Chairs, Banting Research Foundation.
Abstract (Originalsprache)
There are few therapeutic options to treat patients with sickle cell disease (SCD), a blood disorder caused by mutations in the β-globin gene that affects > 7M individuals worldwide. Combining human genetics and high-throughput proteomics can help identify new drug targets. Here, we present results from a proteogenomic analysis of the plasma proteome in SCD patients. We measured the levels of 5,411 plasma proteins and tested their associations with common genetic variation in 343 SCD patients. After conditional analyses, we identified 560 protein quantitative trait loci (pQTL), including 58 (10%) that are novel. Many of these pQTL are not specific to SCD patients and associate with clinically relevant traits in non-SCD African Americans from the Million Veteran Program (e.g., hemoglobin concentration, triglycerides). The effect sizes of the pQTL are largely concordant between SCD and non-SCD individuals, although we found examples (e.g., APOL1, haptoglobin) with evidence of heterogeneity that suggests an interaction between the plasma proteome and the SCD genotype. Finally, we combine pQTL and genome-wide association study results for fetal hemoglobin (HbF) in a Mendelian randomization analysis to prioritize four proteins that may increase HbF production (ENPP5, LBP, PTX3, ZP3). We have combined high-throughput DNA genotyping and plasma proteome profiling to confirm known and identify new genetic variants associated with protein level variation in SCD. Our results provide an opportunity to prioritize novel SCD drug targets that are informed by human genetics.
Autor:innen und Institutionen
- Université de Montréal, Montréal, Québec, Canada.
- Montreal Heart Institute, Montréal, Québec, Canada.
- Red Cell Genetic Disease Unit, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Est, Créteil, France.
ORCID-Profile: Arnaud Chignon, Vanessa Bellegarde, Guillaume Lettre
Förderung
- Institute of Genetics
- Canada Research Chairs
- Banting Research Foundation
- Fonds de recherche du Québec – Nature et technologies
Zitieren
APA
Groza, C., Chignon, A., Lo, K. S., Bellegarde, V., Bartolucci, P., & Lettre, G. (2026). Proteogenomic analysis of 5,411 plasma proteins in sickle cell disease patients. PLOS Genetics, 22(11), e1012377. https://doi.org/10.1371/journal.pgen.1012377
Vancouver
Groza C, Chignon A, Lo KS, Bellegarde V, Bartolucci P, Lettre G. Proteogenomic analysis of 5,411 plasma proteins in sickle cell disease patients. PLOS Genetics. 2026;22(11):e1012377. doi:10.1371/journal.pgen.1012377
BibTeX
@article{Groza2026,
author = {Groza, Cristian and Chignon, Arnaud and Lo, Ken Sin and Bellegarde, Vanessa and Bartolucci, Pablo and Lettre, Guillaume},
title = {Proteogenomic analysis of 5,411 plasma proteins in sickle cell disease patients},
journal = {PLOS Genetics},
year = {2026},
volume = {22},
number = {11},
pages = {e1012377},
doi = {10.1371/journal.pgen.1012377}
}
EUVIMED